Retinoblastoma Program

Opportunities for Research Participation

Physicians and researchers from the Retinoblastoma Program within the Cancer and Blood Diseases Institute at Cincinnati Children’s offer clinical research studies for children with retinoblastoma.

View a complete list of current clinical trials or narrow your search specifically for those related to retinoblastoma.

• ADVL1211: A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents with Recurrent or Refractory Solid Tumors, Including CNS Tumors
• IARB1: A Pilot Study of Intra-Ophthalmic Artery Topotecan Infusion for the Treatment of Retinoblastoma
• ADVL0912: A Phase I/II study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-MET, in children with Relapsed/Refractory Solid Tumors, Primary CNS Tumors, and Anaplastic Large Cell Lymphoma
• ADVL1011: INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
• ADVL1014: A Phase 1 Dose Escalation Study of Reolysin, a Replication Competent Reovirus, in Pediatric Patients With Relapsed or Refractory Solid Tumors
• ADVL0911: A Phase 1 Dose Escalation Study of Seneca Valley Virus (NTX-010), A Replication-Competent Picornavirus, in Relapsed/Refractory Pediatric Patients With Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features
• IARB1: A Pilot Study of Intraophthalmic Artery Topotecan Infusion for the Treatment of Retinoblastoma
• HSV1716: A Phase I Dose Escalation Study of Intratumoral Herpes Simplex Virus-1 Mutant HSV1716 In Patients with Refractory Non-Central Nervous System (Non-CNS) Solid Tumors